ERBB2 and breast carcinoma: Conversely, drugs like rifampin, a potent CYP3A4 inducer, can alter the metabolism of lapatinib (used in HER2-positive breast cancer), leading to the formation of potentially hepatotoxic metabolites or decreased hepatic clearance.